The fastest way to detect liver steatosis.
Just one ultrasound image is enough for a reliable analysis in seconds.
Clinically validated technology, ready to use.
Built for doctors, designed around patients. No change to your workflow.
94%
accuracy in detecting liver steatosis over 7%, alidated by clinical studies.
“It’s incredibly fast, simple to use, and seamlessly fits into our workflow. A real game-changer for liver screening.”
What is USe and why it matters
Fatty liver affects 1 in 4 people globally, but diagnosis is often delayed due to cost or lack of tools.
USe allows you to detect liver steatosis in less than 20 seconds using a single ultrasound image — no additional scans, no workflow changes.
It’s a non-invasive, AI-powered solution, validated in clinical trials and already improving care in real practices.
Overview
Hepatic Steatosis is the most common liver disease, it affects one third of global population. It is an important risk factor for liver, methabolic and cardiovascular disease. Un diagnosed steatosis can lead to cirrhosis and hepatocarcinoma. The golden standards for accurate diagnosis are agobiopsy and magnetic resonance proton density fat fraction. This techniques are expensive and/or invasive. In the last 10 years ultrasound examination established as an economic and non-invasive alternative but it has some big disadvantages: it is imprecise and not accurate, it is affected by human variability in execution of exam and in evaluation and moreover the human eye cannot accurately detect fat below 19% (wich is considerated a severe grade of steatosis). Scientific and clinical communities need an economic and non-invasive tool that can be used for mass-screening purposes and a tool for follow up of patient.
USe (Ultrasound Steatosis evaluator) is an AI aided tool that is able analyze a single US image and evaluate accurately the presence of fat above 7% in liver. Sergio Santoro published in collaboration with University of Bari Aldo Moro on European Journal of Internal Medicine https://doi.org/10.1016/j.ejim.2024.03.004 the results of a clinical trial. In the clinical trial the research team compared USe to the Magnetic Resonance Proton Density Fat Fraction (wich is considered gold standard) and obtained very good results. Sergio Santoro applied for patent in collaboration with University of Bari Aldo Moro. At the moment USe is the unique solution that can evaluate precisely and automatically the hepatorenal index.
Main advantages of USe are
- speed (only 20 sec for the evaluation),
- cost (it’s the cheapest accurate solution),
- automation (fully automated).
Patent
WO2024252170 6 June 2023 – 50% property of Università degli Studi di Bari Aldo Moro